Keyword: Kendall Square

German pharma Bayer is looking to boost its research presence in the life science hub Kendall Square amid a 12,000 global job cull.

Headed by Don Frail, the Kendall Square group will work to connect Allergan to VC groups and startups in the Cambridge, Massachusetts, hot spot.

The French drugmaker is the latest in a series of European companies to pick the biotech hotspot as their U.S. base.

News of the office opening comes shortly after the French company stepped up its U.S. strategy with a $2.4 billion deal for Shire’s oncology unit.

Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.

Flagship Pioneering’s quiet oncology upstart Torque Therapeutics has filed a $21 million raise as it lands in Kendall Square.

Shire is expanding its innovation play in Cambridge, MA, as it looks to boost its presence in Kendall Square and create a 550,000-square-foot campus focused on rare diseases.

Dermatology pharma LEO has gained the seal of approval for its newly opened Science & Tech Hub in Boston by Her Royal Highness, Crown Princess Mary of Denmark.

A biotech borne out of a JV between Bayer’s new research deals arm and CRISPR Therapeutics will start operations at life sciences hub Kendall Square in Cambridge, MA, next year as looks to get to work on a number of disease areas using the new CRISPR-Cas9 cutting-edge tech.